SecBot SecBot
PRESS-RELEASE ·Filed Mar 23, 2026

APGE

Apogee Therapeutics
BEARISH
Impact 7/10
Horizonimmediate Processed7mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

Traders should anticipate near-term downside pressure due to share dilution and potential insider sentiment concerns; monitor pricing and final size of the offering, as well as use of proceeds for pipeline advancement signals.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$73.00
T+0 close · Mar 23, 2026 · via day close
Latest settled
+23.81%
T+60 · $90.38
Vs SPY
+9.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 24 $73.00entry
  2. T+1 · 8mo ago +7.58%α +7.01% · $78.53
  3. T+5 · 8mo ago +15.30%α +15.72% · $84.17
  4. T+20 · 7mo ago +24.22%α +15.32% · $90.68
  5. T+60 · 5mo ago +23.81%α +9.48% · $90.38
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics (APGE) has announced a $300 million public offering of common stock, with an additional $45 million option for underwriters, to fund clinical development and general corporate purposes. The offering represents significant near-term dilution and is being conducted amid recent insider selling.

Key Financial Metrics

Deal Value
$345.0M

Key Facts

  • Apogee Therapeutics is conducting a $300 million public offering of common stock.
  • Underwriters have a 30-day option to purchase up to an additional $45 million in shares.
  • Proceeds will fund preclinical/clinical trials, manufacturing, commercial readiness, R&D, and general corporate purposes.
  • Recent insider activity includes two sales totaling $642K in the past 30 days.
  • The offering is made under an effective shelf registration filed August 12, 2024.

Financial Impact

$300 million raised, expandable to $345 million; significant dilution expected depending on pricing and outstanding share count

dilutioncashequity

Risk Factors

  • Dilution from new share issuance could pressure stock price
  • Insider selling concurrent with capital raise may signal lack of confidence
  • Biotech clinical-stage risk: no revenue, dependence on trial outcomes and funding runway

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3260824

Track record

31 reports on APGE

Performance horizon

9 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 12 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (11h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 23, 2026